Cancer Immunotherapy
The aim of this website is to inform the public about the original tumor immunotherapy, with which we achieve an 80% cure, suppress metastases and gain resistance to disease recurrence in mouse models of melanoma, sarcoma, pancreatic adenocarcinoma, colorectal cancer, pheochromocytoma, breast tumor and glioblastoma.
We strive to translate our knowledge into clinical practice. This process is very costly and time-consuming, it usually takes 12–14 years. Recently we have seen in the context of covid that everything can be shortened to 6 months. We believe that we will find the support of a strong pharmaceutical company allowing us to introduce our tumor immunotherapy into practice soon. Millions of patients are waiting for it.
An example of the effect of our therapy:
the killing of melanoma cell by neutrophil
Time-lapse video showing neutrophil action against melanoma cells in vitro
An accelerated record of the action lasting 45 minutes. Large cells are melanoma cells; small cells are neutrophils. The arrow indicates a melanoma cell that succumbs to a neutrophil attack. The recording was made by Nikol Vácová.
Want to learn more?
Discover the details of our therapy, explore the science behind it,
and watch presentations from our team.
Support the development of MBTA immunotherapy
If you wish to support the further development, validation, and responsible translation of MBTA cancer immunotherapy, you can do so through our independent Cancer Immunotherapy Endowment Fund (CIEF).